Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Collaborator: Pharmacia and Upjohn
• Treatments: Irinotecan; Mitomycin; Mitomycins

Criteria

Inclusion Criteria:

• Must have pathologically confirmed & measurable advanced esophageal or Gastroesophageal junction adenocarcinoma

• No prior chemotherapy

• Prior radiation allowed if <=20% of bone marrow was irradiated

• Target lesions must not be in radiation field.